 Connection
Charles Dinarello to Antibodies, Monoclonal
This is a "connection" page, showing publications Charles Dinarello has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.368 |
|
|
|
-
Li S, Jiang L, Beckmann K, Højen JF, Pessara U, Powers NE, de Graaf DM, Azam T, Lindenberger J, Eisenmesser EZ, Fischer S, Dinarello CA. A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling. J Biol Chem. 2021 Jan-Jun; 296:100630.
Score: 0.399
-
Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M, Beckman K, Fujita M, Fischer S, Dinarello CA. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 09; 20(9):1138-1149.
Score: 0.356
-
Dinarello CA, Joosten LA. Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis. Nat Rev Rheumatol. 2016 Feb; 12(2):78-80.
Score: 0.278
-
Dinarello CA. Interleukin-1a neutralisation in patients with cancer. Lancet Oncol. 2014 May; 15(6):552-3.
Score: 0.246
-
Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med. 2009 Jun 04; 360(23):2467-70.
Score: 0.176
-
Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl. 2005 Mar; 74:40-7.
Score: 0.131
-
Ghezzi P, Fantuzzi G, Dinarello CA. Perspective: Daniela Novick, cytokines and their receptors. Front Immunol. 2023; 14:1160651.
Score: 0.115
-
Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1a in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol. 2021 Jan; 46(1):162-163.
Score: 0.095
-
Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN. Blocking IL-1ß reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019 01 22; 116(4):1361-1369.
Score: 0.085
-
Tunjungputri RN, Li Y, de Groot PG, Dinarello CA, Smeekens SP, Jaeger M, Doppenberg-Oosting M, Cruijsen M, Lemmers H, Toenhake-Dijkstra H, Aguirre-Gamboa R, Kumar V, Wijmenga C, Joosten LAB, Netea MG, van der Ven A, de Mast Q. The Inter-Relationship of Platelets with Interleukin-1ß-Mediated Inflammation in Humans. Thromb Haemost. 2018 Dec; 118(12):2112-2125.
Score: 0.085
-
Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 Targeting IL-1a for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol. 2018 04; 138(4):795-801.
Score: 0.079
-
Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015 Dec; 54(12):2134-44.
Score: 0.067
-
Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013 Dec 15; 25(6):469-84.
Score: 0.060
-
Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012 Aug; 11(8):633-52.
Score: 0.055
-
Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, Yu DY, Song EY, Lee HG, Sohn JH, Kim J, Dinarello CA, Yoon DY. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J Immunol Methods. 2008 Apr 20; 333(1-2):38-50.
Score: 0.040
-
Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E. The role of IL-1ß in the early tumor cell-induced angiogenic response. J Immunol. 2013 Apr 01; 190(7):3500-9.
Score: 0.014
-
Mancilla J, Ikejima T, Dinarello CA. Glycosylation of the interleukin-1 receptor type I is required for optimal binding of interleukin-1. Lymphokine Cytokine Res. 1992 Aug; 11(4):197-205.
Score: 0.014
-
Dinarello CA. ELISA kits based on monoclonal antibodies do not measure total IL-1 beta synthesis. J Immunol Methods. 1992 Apr 08; 148(1-2):255-9.
Score: 0.013
-
Williams JM, Deloria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM, Strom TB. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol. 1985 Oct; 135(4):2249-55.
Score: 0.009
-
Kaye J, Gillis S, Mizel SB, Shevach EM, Malek TR, Dinarello CA, Lachman LB, Janeway CA. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol. 1984 Sep; 133(3):1339-45.
Score: 0.008
-
Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004 Apr; 13(4):193-222.
Score: 0.008
-
Stuyt RJ, Kim SH, Reznikov LL, Fantuzzi G, Novick D, Rubinstein M, Kullberg BJ, van der Meer JW, Dinarello CA, Netea MG. Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine. 2003 Jan 21; 21(2):65-73.
Score: 0.007
-
Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, Dinarello CA, Rubinstein M. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001 Jun 21; 14(6):334-42.
Score: 0.006
-
Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol. 1996 Jul; 24(8):868-74.
Score: 0.004
-
Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1. Mol Med. 1995 Sep; 1(6):667-77.
Score: 0.004
-
Cohen AB, MacArthur C, Idell S, Maunder R, Martin T, Dinarello CA, Griffith D, McLarty J. A peptide from alveolar macrophages that releases neutrophil enzymes into the lungs in patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1988 May; 137(5):1151-8.
Score: 0.003
-
Jandl RC, George JL, Dinarello CA, Schur PH. The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus. Clin Immunol Immunopathol. 1987 Dec; 45(3):384-94.
Score: 0.002
-
Fauci AS, Rosenberg SA, Sherwin SA, Dinarello CA, Longo DL, Lane HC. NIH conference. Immunomodulators in clinical medicine. Ann Intern Med. 1987 Mar; 106(3):421-33.
Score: 0.002
-
Lotz M, Tsoukas CD, Robinson CA, Dinarello CA, Carson DA, Vaughan JH. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J Clin Invest. 1986 Sep; 78(3):713-21.
Score: 0.002
-
Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986 May 01; 136(9):3239-45.
Score: 0.002
-
Chedid L, Bahr GM, Modabber FZ, Dinarello CA, Wolff SM. [Demonstration of a bacterial structure in two human mediators: a sleep facilitating factor and a monokine]. C R Seances Acad Sci III. 1983; 297(4):209-12.
Score: 0.002
-
McAdam KP, Li J, Knowles J, Foss NT, Dinarello CA, Rosenwasser LJ, Selinger MJ, Kaplan MM, Goodman R, Herbert PN, Bausserman LL, Nadler LM. The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. Ann N Y Acad Sci. 1982; 389:126-36.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|